

# Clinical Trial Development of A Novel Small Molecule Inhibitor for Idiopathic Pulmonary Fibrosis Treatment

Daewoong Pharmaceutical Co., Ltd.



RESPIRATORY	Phase II
Product Type	New Molecular Entity (NME)
Indication	Idiopathic Pulmonary Fibrosis (Orphan drug)
Target	Prolyl-tRNA Synthetase
MoA(Mechanism of Action)	Down-regulating collagen synthesis through inhibiting PRS
Competitiveness	<p>First-in-Class product</p> <p>Directly targets collagen synthesis, the end product of fibrosis, and can inhibit various fiber factors</p> <p>Secured superior efficacy results when administered in combination with approved treatments</p>
Development Stage	Phase II
Route of Administration	Oral